While there is an abundance of evidence highlighting the use of both pan and isoform-specific ALDH inhibitors as anti-cancer agents, none have progressed into clinics, namely, due to working concentrations that surpass those required for clinical translation. This evidence concerns the gene LDHA and cancer.